New research confirms role of heart disease as a treatment by-product.
Various antiretroviral drugs lead to metabolic and morphologic problems, according to the body of evidence now available to HIV clinicians for review. However, how HIV physicians should react to this situation when patients have the long-term side effects remains debatable. While discontinuation of certain drugs may be advisable in some cases; in others, the risks may outweigh the benefits of switching regimens.
D015658:HIV Infections / Q000150:complications / Q000188:drug therapy; D017320:HIV Protease Inhibitors / Q000009:adverse effects*; D006331:Heart Diseases / Q000139:chemically induced* / Q000150:complications; D006801:Humans; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects*
D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors